The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam, MD, City of Hope, Duarte, CA, discusses the updated preliminary safety, efficacy, and pharmacokinetics data from a Phase I study (NCT06254495) of a novel CD30-directed antibody-drug conjugate in patients with relapsed/refractory (R/R) lymphomas. Dr Thiruvengadam highlights that the agent is showing promising efficacy with a well-tolerated toxicity profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
